Navigation Links
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
Date:1/12/2009

MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced continued progress with its two Phase 3 clinical programs, Unit Dose Budesonide (UDB) for children with asthma and MAP0004 for the acute treatment of migraine. For UDB, all patients have completed the 12 week treatment period in the initial Phase 3 clinical trial, and for MAP0004, the company currently expects to complete enrollment in its initial Phase 3 clinical trial by the end of January 2009.

"We continue to make good progress with our Phase 3 asthma and migraine programs and look forward to reporting data from both programs during the first half of 2009," said Timothy S. Nelson, President and CEO of MAP Pharmaceuticals. "We believe this clinical progress coupled with our recently announced asthma partnership with AstraZeneca highlights the value of our clinical approach and business strategy."

UDB Phase 3 Program

The initial UDB Phase 3 clinical trial completed enrollment in September 2008, and all patients now have completed the treatment period. This Phase 3 trial is a multi-center, randomized, double-blind, placebo controlled trial in approximately 360 children who suffer from asthma, from 12 months to 8 years of age. Patients received either 0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12 week treatment period. The co-primary efficacy endpoints for the study are the change in nighttime and daytime composite symptom scores (cough, wheeze and breathlessness). Patients enrolled in this trial will continue to be followed in a long-term safety trial.

UDB is being studied as a novel version of nebulized budesonide. Budesonide has been used clinically for more than 20 years. UDB is designed to be nebulized more quickly and at a lower nominal dose than th
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... August 26, 2014 New research ... wearable technology, and inspiration for the International Year ... year’s brighter, busier SPIE Optics + Photonics ... More than 4,400 international scientists, engineers, researchers, developers, ... exhibition, and industry sessions sponsored by SPIE, ...
(Date:8/26/2014)... team of engineers from Singapore has successfully piloted ... for satellite communications. , With the weight of ... constructing a lightweight, low power-consuming, wireless communication system ... has always been a challenge for system designers. ... Centre of Nanyang Technological University in Singapore launched ...
(Date:8/26/2014)... Aug. 26, 2014 An analysis by Replikins, ... all Dengue virus strains in Pubmed, has revealed extensive ... 1944. This conservation and sharing of specific Replikin gene ... Blocker-Vaccine™ candidate, as it did for the H5N1 influenza ... which have been found to be effective (1,2). ...
(Date:8/26/2014)... , Aug. 26, 2014 Technology Applications ... symbol (NUUU) has two (2) wholly- owned subsidiaries, ... subsidiaries harness scientifically advanced technology to provide advanced ... NUUU,s Renuell Int,l, Inc. is launching its ... care products that is made possible because of ...
Breaking Biology Technology:Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ZigBee in the Sky 2Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2
... the, prior year,s third quarter - Earnings per share of $0.28, ... cash flow of $23 million, (Year-to-date operating cash flow of $62 million) ... ... Biosciences,Corporation (Nasdaq: MATK ) today announced its financial results for the,third ...
... The Hamner Institutes and The University of North Carolina-Chapel ... Research Partnership in Drug Safety Sciences, RESEARCH TRIANGLE ... Sciences and the University of North Carolina at,Chapel Hill ... Safety,Sciences that will be led by Dr. Paul Watkins, ...
... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, today announced that ... common stock which will begin trading under the ... common stock will no longer trade,under the symbol ...
Cached Biology Technology:Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3
(Date:8/27/2014)... A growing number of studies have shown ... the pathogenesis of Parkinson,s disease. Previous studies ... Medical University in China have shown that ... injury, reduced divalent metal transporter 1 expression, ... substantia nigra of rotenone-induced Parkinson,s disease rats. ...
(Date:8/27/2014)... Happy Camp Complex of fires had consumed 24,939 acres ... consumed 35,530 as of eight hours ago. , ... Ranger District of the Klamath National Forest when a ... All but three of those fires are now 100 ... fires and their size at containment: Delta, 150 acres; ...
(Date:8/27/2014)... Carolina State University have found that century-old museum specimens hold ... insect pest that can weaken and kill trees and ... scale insect populations increase on oak and maple trees in ... may also increase with global warming," says Dr. Elsa Youngsteadt, ... a paper on the work. , "More scale insects would ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... and microorganisms, Systems Biology is regarded as the next ... allow biologists to spell all the letters in the ... way of deciphering this complex code. Pharma- and biotechnology ... tools for use in drug discovery and development., Systems ...
... cells, high school students and teachers sounds like a witches brew ... Instead, these are the components that ... curriculum being developed by researchers at Washington University in St. Louis ... Lars Angenent, Ph.D., assistant ...
... Commonwealth University Massey Cancer Center research team has received ... National Cancer Institute to improve the activity of a ... in the treatment of leukemia and other blood malignancies. ... associate director for translational research and co-leader of the ...
Cached Biology News:World class in Systems Biology is the aim 2World class in Systems Biology is the aim 3World class in Systems Biology is the aim 4Microbial fuel cells turn on the juice 2Microbial fuel cells turn on the juice 3NCI renewal grant to develop new cancer therapies 2
...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: